2026 Q1 -tulosraportti
Vain PDF
10 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 7.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 9.3. | ||
2025 Q3 -tulosraportti 10.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
2 päivää sitten2 päivää sittenMay 14th: Biogen announced that the Phase 2 CELIA trial of diranersen (BIIB080) successfully demonstrated both a robust reduction in tau pathology and a statistically significant cognitive benefit in patients with early Alzheimer’s disease. The market is quickly identifying Voyager as a key beneficiary of Biogen's validation event:Validating the Technology Modality: Biogen used an antisense oligonucleotide (ASO) that requires invasive intrathecal spinal taps every 12 to 24 weeks to temporarily turn down tau mRNA. Voyager’s VY1706 program utilizes a one-time intravenous IV arm drip to achieve the exact same gene-silencing mechanism.Immediate De-risking: The biggest risk holding back Voyager’s valuation was whether lowering tau inside human neurons would actually stop cognitive decline. Today, Biogen proved to the world that it does. Based on a fundamental financial assessment of the biotechnology sector as of May 2026, Voyager Therapeutics (NASDAQ: VYGR) is significantly undervalued relative to its asset base and intellectual property. Public market pricing reflects distinct systemic micro-cap and sector pressures rather than technical deficiencies:The "Pre-Clinical" Discount: Until a biotech company doses its first human patient, the market heavily discounts its assets. Because VY1706 (Alzheimer's) and NBIB-223 (Friedreich’s Ataxia) are only just filing INDs in Q2 2026, algorithmic and institutional funds treat Voyager as a pre-clinical platform. Voyager is trading like a distressed biotech startup running out of money, despite holding a robust $172 million cash cushion, partnerships with Novartis and AstraZeneca, and active clinical trial entry scheduled for H2 2026. For long-term investors tracking genetic medicine platforms, this is a classic valuation anomaly However, today (May 14th) Biogen’s Phase 2 CELIA readout released today represents a historic, paradigm-shifting victory for the Alzheimer’s space. By demonstrating that targeting tau directly slows cognitive decline, Biogen has fundamentally validated the entire biological thesis that underpins Voyager Therapeutics’ platform. Validating the Technology Modality: Biogen used an antisense oligonucleotide (ASO) that requires invasive intrathecal spinal taps every 12 to 24 weeks to temporarily turn down tau mRNA. Voyager’s VY1706 program utilizes a one-time intravenous IV arm drip to achieve the exact same gene-silencing mechanism.Immediate De-risking: The biggest risk holding back Voyager’s valuation was whether lowering tau inside human neurons would actually stop cognitive decline. Today, Biogen proved to the world that it does. Given a choice between a lifelong routine of painful spinal injections at an outpatient center (Biogen) or a single, one-time IV arm drip that continuously clears tau for years (Voyager), the market will naturally lean toward the non-invasive gene therapy vector. The core value of Voyager Therapeutics does not lie in its individual drug pipeline, but in its proprietary TRACER™ (Tropism Receptor Accelerated CNN-based Evolution Research) AAV Capsid Discovery Platform.In genetic medicine, the drug itself (the RNA or DNA blueprint) is relatively easy to manufacture. The multi-billion-dollar bottleneck is delivery—getting that blueprint safely inside the correct human cells. Voyager has solved the hardest delivery problem in medicine: safely crossing the Blood-Brain Barrier (BBB) via a standard intravenous (IV) infusion [1, 2]. Licensing contracts are in place with Novartis, AstraZeneca and Neurocrine. The Neurocrine Biosciences partnership utilizes Voyager's capsids for Friedreich’s Ataxia (NBIB-223) and GBA1-related Parkinson's disease. This deal brings a milestone runway exceeding $1.5 billion, alongside standard double-digit commercial royalties. Put/Call Volume Ratio: 0.00. During active trading, options desks reported a total of 343 Call contracts traded against 0 Put contracts. This represents pure upside speculation with zero localized downside hedging. Potential for a rolling-squeeze: Days to Cover Ratio: 5.6 Days. Based on a 30-day average daily volume of 675,663 shares, it would take short sellers over a full week of average market liquidity to repurchase and close out their positions https://www.fiercebiotech.com/biotech/biogen-advances-alzheimers-tau-program-despite-midphase-miss (dosing miss = lowest dose was effective and higher doses was not needed, so best miss in the world) Nobel prize soon for Alzheimer's treatment?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
10 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 päivää sitten2 päivää sittenMay 14th: Biogen announced that the Phase 2 CELIA trial of diranersen (BIIB080) successfully demonstrated both a robust reduction in tau pathology and a statistically significant cognitive benefit in patients with early Alzheimer’s disease. The market is quickly identifying Voyager as a key beneficiary of Biogen's validation event:Validating the Technology Modality: Biogen used an antisense oligonucleotide (ASO) that requires invasive intrathecal spinal taps every 12 to 24 weeks to temporarily turn down tau mRNA. Voyager’s VY1706 program utilizes a one-time intravenous IV arm drip to achieve the exact same gene-silencing mechanism.Immediate De-risking: The biggest risk holding back Voyager’s valuation was whether lowering tau inside human neurons would actually stop cognitive decline. Today, Biogen proved to the world that it does. Based on a fundamental financial assessment of the biotechnology sector as of May 2026, Voyager Therapeutics (NASDAQ: VYGR) is significantly undervalued relative to its asset base and intellectual property. Public market pricing reflects distinct systemic micro-cap and sector pressures rather than technical deficiencies:The "Pre-Clinical" Discount: Until a biotech company doses its first human patient, the market heavily discounts its assets. Because VY1706 (Alzheimer's) and NBIB-223 (Friedreich’s Ataxia) are only just filing INDs in Q2 2026, algorithmic and institutional funds treat Voyager as a pre-clinical platform. Voyager is trading like a distressed biotech startup running out of money, despite holding a robust $172 million cash cushion, partnerships with Novartis and AstraZeneca, and active clinical trial entry scheduled for H2 2026. For long-term investors tracking genetic medicine platforms, this is a classic valuation anomaly However, today (May 14th) Biogen’s Phase 2 CELIA readout released today represents a historic, paradigm-shifting victory for the Alzheimer’s space. By demonstrating that targeting tau directly slows cognitive decline, Biogen has fundamentally validated the entire biological thesis that underpins Voyager Therapeutics’ platform. Validating the Technology Modality: Biogen used an antisense oligonucleotide (ASO) that requires invasive intrathecal spinal taps every 12 to 24 weeks to temporarily turn down tau mRNA. Voyager’s VY1706 program utilizes a one-time intravenous IV arm drip to achieve the exact same gene-silencing mechanism.Immediate De-risking: The biggest risk holding back Voyager’s valuation was whether lowering tau inside human neurons would actually stop cognitive decline. Today, Biogen proved to the world that it does. Given a choice between a lifelong routine of painful spinal injections at an outpatient center (Biogen) or a single, one-time IV arm drip that continuously clears tau for years (Voyager), the market will naturally lean toward the non-invasive gene therapy vector. The core value of Voyager Therapeutics does not lie in its individual drug pipeline, but in its proprietary TRACER™ (Tropism Receptor Accelerated CNN-based Evolution Research) AAV Capsid Discovery Platform.In genetic medicine, the drug itself (the RNA or DNA blueprint) is relatively easy to manufacture. The multi-billion-dollar bottleneck is delivery—getting that blueprint safely inside the correct human cells. Voyager has solved the hardest delivery problem in medicine: safely crossing the Blood-Brain Barrier (BBB) via a standard intravenous (IV) infusion [1, 2]. Licensing contracts are in place with Novartis, AstraZeneca and Neurocrine. The Neurocrine Biosciences partnership utilizes Voyager's capsids for Friedreich’s Ataxia (NBIB-223) and GBA1-related Parkinson's disease. This deal brings a milestone runway exceeding $1.5 billion, alongside standard double-digit commercial royalties. Put/Call Volume Ratio: 0.00. During active trading, options desks reported a total of 343 Call contracts traded against 0 Put contracts. This represents pure upside speculation with zero localized downside hedging. Potential for a rolling-squeeze: Days to Cover Ratio: 5.6 Days. Based on a 30-day average daily volume of 675,663 shares, it would take short sellers over a full week of average market liquidity to repurchase and close out their positions https://www.fiercebiotech.com/biotech/biogen-advances-alzheimers-tau-program-despite-midphase-miss (dosing miss = lowest dose was effective and higher doses was not needed, so best miss in the world) Nobel prize soon for Alzheimer's treatment?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 7.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 9.3. | ||
2025 Q3 -tulosraportti 10.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
10 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 7.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 9.3. | ||
2025 Q3 -tulosraportti 10.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 päivää sitten2 päivää sittenMay 14th: Biogen announced that the Phase 2 CELIA trial of diranersen (BIIB080) successfully demonstrated both a robust reduction in tau pathology and a statistically significant cognitive benefit in patients with early Alzheimer’s disease. The market is quickly identifying Voyager as a key beneficiary of Biogen's validation event:Validating the Technology Modality: Biogen used an antisense oligonucleotide (ASO) that requires invasive intrathecal spinal taps every 12 to 24 weeks to temporarily turn down tau mRNA. Voyager’s VY1706 program utilizes a one-time intravenous IV arm drip to achieve the exact same gene-silencing mechanism.Immediate De-risking: The biggest risk holding back Voyager’s valuation was whether lowering tau inside human neurons would actually stop cognitive decline. Today, Biogen proved to the world that it does. Based on a fundamental financial assessment of the biotechnology sector as of May 2026, Voyager Therapeutics (NASDAQ: VYGR) is significantly undervalued relative to its asset base and intellectual property. Public market pricing reflects distinct systemic micro-cap and sector pressures rather than technical deficiencies:The "Pre-Clinical" Discount: Until a biotech company doses its first human patient, the market heavily discounts its assets. Because VY1706 (Alzheimer's) and NBIB-223 (Friedreich’s Ataxia) are only just filing INDs in Q2 2026, algorithmic and institutional funds treat Voyager as a pre-clinical platform. Voyager is trading like a distressed biotech startup running out of money, despite holding a robust $172 million cash cushion, partnerships with Novartis and AstraZeneca, and active clinical trial entry scheduled for H2 2026. For long-term investors tracking genetic medicine platforms, this is a classic valuation anomaly However, today (May 14th) Biogen’s Phase 2 CELIA readout released today represents a historic, paradigm-shifting victory for the Alzheimer’s space. By demonstrating that targeting tau directly slows cognitive decline, Biogen has fundamentally validated the entire biological thesis that underpins Voyager Therapeutics’ platform. Validating the Technology Modality: Biogen used an antisense oligonucleotide (ASO) that requires invasive intrathecal spinal taps every 12 to 24 weeks to temporarily turn down tau mRNA. Voyager’s VY1706 program utilizes a one-time intravenous IV arm drip to achieve the exact same gene-silencing mechanism.Immediate De-risking: The biggest risk holding back Voyager’s valuation was whether lowering tau inside human neurons would actually stop cognitive decline. Today, Biogen proved to the world that it does. Given a choice between a lifelong routine of painful spinal injections at an outpatient center (Biogen) or a single, one-time IV arm drip that continuously clears tau for years (Voyager), the market will naturally lean toward the non-invasive gene therapy vector. The core value of Voyager Therapeutics does not lie in its individual drug pipeline, but in its proprietary TRACER™ (Tropism Receptor Accelerated CNN-based Evolution Research) AAV Capsid Discovery Platform.In genetic medicine, the drug itself (the RNA or DNA blueprint) is relatively easy to manufacture. The multi-billion-dollar bottleneck is delivery—getting that blueprint safely inside the correct human cells. Voyager has solved the hardest delivery problem in medicine: safely crossing the Blood-Brain Barrier (BBB) via a standard intravenous (IV) infusion [1, 2]. Licensing contracts are in place with Novartis, AstraZeneca and Neurocrine. The Neurocrine Biosciences partnership utilizes Voyager's capsids for Friedreich’s Ataxia (NBIB-223) and GBA1-related Parkinson's disease. This deal brings a milestone runway exceeding $1.5 billion, alongside standard double-digit commercial royalties. Put/Call Volume Ratio: 0.00. During active trading, options desks reported a total of 343 Call contracts traded against 0 Put contracts. This represents pure upside speculation with zero localized downside hedging. Potential for a rolling-squeeze: Days to Cover Ratio: 5.6 Days. Based on a 30-day average daily volume of 675,663 shares, it would take short sellers over a full week of average market liquidity to repurchase and close out their positions https://www.fiercebiotech.com/biotech/biogen-advances-alzheimers-tau-program-despite-midphase-miss (dosing miss = lowest dose was effective and higher doses was not needed, so best miss in the world) Nobel prize soon for Alzheimer's treatment?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt